Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the cureihus study

HIGHLIGHTS

• who: Romy N. Bouwmeester from the DepartmentRadboud University for Health Sciences, Nijmegen, the Netherlands have published the article: Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study, in the Journal: (JOURNAL) of 18/Oct/2022
• what: The authors report the results of the CUREiHUS study, a 4-year prospective, observational study monitoring unbiased eculizumab discontinuation in Dutch patients with aHUS after 3 months of therapy. The median time of eculizumab treatment (range 2.4-19.6 months) varies greatly between cohorts . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.